Entrectinib (ROZLYTREK) is a Category 2A (preferred) option for first-line treatment of patients with ROS1 rearrangement positive metastatic NSCLC in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 3a,b
aWhen a ROS1 rearrangement is discovered prior
to, or during, first-line systemic therapy.
bThe National Comprehensive Cancer Network® (NCCN) makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Dosing and Administration
Learn about the dosing and administration of ROZLYTREK
Learn about the safety profile of ROZLYTREK
Financial and Other Resources
Learn more about financial and other resources for ROZLYTREK